Cara Therapeutics Inc (CARA) stock has risen 5.04% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives CARA stock a score of 55 out of a possible 100. That rank is mainly influenced by a fundamental score of 67. In addition to the average rating from Wall Street analysts, CARA stock has a mean target price of $26.13. This means analysts expect the stock to climb 58.72% over the next 12 months. CARA's rank also includes a long-term technical score of 64. The short-term technical score for CARA is 34.
CARA has an Overall Score of 55. Find out what this means to you and get the rest of the rankings on CARA!